Stock listing
NASDAQ:JUNS Jupiter Neurosciences, Inc. Stock
Home listing (NASDAQ) of Jupiter Neurosciences, Inc.
Follow Jupiter Neurosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:JUNS
$1.24 USD -0.28 (-18.7%)
Close on Nov 20, 2026
- Day range
- $1.20 – $1.46 USDNov 20, 2026
- Volume
- 20,106 sharesNov 20, 2026
- Market cap
- $1.63M USDAt the close on Nov 20, 2026 · price × 1.32M shares outstanding
- 52-week range
- $1.20 – $97.74 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.25M USDMedian day 23,593 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:JUNS · Home | $1.235 USD | -0.285 (-18.7%) | 20,106 | $1.46 | $1.46 | $1.20 | $1.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JUNS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.235 | -0.285 | -18.7% | $1.46 | $1.46 | $1.20 | 20,106 | |
| $1.52 | 0.00 | 0.0% | $1.45 | $1.55 | $1.37 | 14,933 | |
| $1.52 | -0.18 | -10.6% | $1.625 | $1.65 | $1.474 | 11,211 | |
| $1.70 | -0.06 | -3.4% | $1.82 | $1.82 | $1.63 | 11,772 | |
| $1.76 | -0.10 | -5.4% | $1.86 | $1.885 | $1.76 | 12,532 | |
| $1.86 | -0.28 | -13.1% | $2.13 | $2.34 | $1.785 | 44,027 | |
| $2.14 | -0.08 | -3.6% | $2.20 | $2.20 | $2.14 | 8,837 | |
| $2.22 | +0.02 | +0.9% | $2.29 | $2.29 | $2.15 | 7,816 | |
| $2.20 | 0.00 | 0.0% | $2.208 | $2.295 | $2.194 | 6,730 | |
| $2.20 | +0.07 | +3.3% | $2.10 | $2.27 | $2.01 | 24,714 | |
| $2.13 | -0.33 | -13.4% | $2.36 | $2.36 | $2.082 | 23,593 | |
| $2.46 | +0.03 | +1.2% | $2.44 | $2.50 | $2.24 | 19,723 | |
| $2.43 | +0.12 | +5.2% | $2.37 | $2.47 | $2.27 | 7,415 | |
| $2.31 | +0.26 | +12.7% | $2.11 | $2.43 | $2.10 | 31,644 | |
| $2.05 | -0.32 | -13.5% | $2.40 | $2.41 | $2.05 | 17,256 | |
| $2.37 | -0.13 | -5.2% | $2.56 | $2.56 | $2.36 | 7,172 | |
| $2.50 | -0.14 | -5.3% | $2.62 | $2.70 | $2.40 | 29,722 | |
| $2.64 | -0.22 | -7.7% | $2.86 | $2.91 | $2.64 | 41,541 | |
| $2.86 | -0.12 | -4.0% | $3.00 | $3.01 | $2.717 | 12,669 | |
| $2.98 | +0.40 | +15.5% | $2.58 | $3.09 | $2.58 | 19,625 | |
| $2.58 | -0.20 | -7.2% | $2.76 | $2.76 | $2.551 | 10,140 | |
| $2.78 | -0.02 | -0.7% | $2.75 | $2.80 | $2.631 | 28,572 | |
| $2.80 | +0.05 | +1.8% | $2.75 | $3.24 | $2.75 | 10,408 | |
| $2.75 | -0.155 | -5.3% | $2.77 | $2.82 | $2.75 | 8,488 | |
| $2.905 | -0.235 | -7.5% | $3.09 | $3.115 | $2.881 | 13,924 | |
| $3.14 | -0.05 | -1.6% | $3.16 | $3.27 | $3.025 | 19,811 | |
| $3.19 | -0.17 | -5.1% | $3.30 | $3.43 | $3.07 | 20,925 | |
| $3.36 | +0.32 | +10.5% | $3.00 | $3.50 | $3.00 | 71,300 | |
| $3.04 | +0.19 | +6.7% | $2.89 | $3.04 | $2.76 | 37,200 | |
| $2.85 | +0.08 | +2.9% | $2.83 | $2.89 | $2.67 | 7,000 | |
| $2.77 | -0.07 | -2.5% | $2.70 | $2.85 | $2.66 | 36,800 | |
| $2.84 | -0.02 | -0.7% | $2.61 | $2.858 | $2.58 | 47,100 | |
| $2.86 | +0.44 | +18.2% | $2.38 | $3.18 | $2.251 | 924,100 | |
| $2.42 | -0.13 | -5.1% | $2.425 | $2.55 | $2.33 | 14,900 | |
| $2.55 | +0.05 | +2.0% | $2.50 | $2.60 | $2.50 | 11,600 | |
| $2.50 | +0.06 | +2.5% | $2.57 | $2.57 | $2.39 | 13,300 | |
| $2.44 | -0.14 | -5.4% | $2.51 | $2.61 | $2.35 | 16,800 | |
| $2.58 | +0.07 | +2.8% | $2.54 | $2.60 | $2.38 | 14,900 | |
| $2.51 | -0.16 | -6.0% | $2.67 | $2.67 | $2.40 | 53,000 | |
| $2.67 | -0.215 | -7.5% | $2.82 | $2.966 | $2.67 | 58,900 | |
| $2.885 | -0.085 | -2.9% | $3.06 | $3.06 | $2.80 | 36,800 | |
| $2.97 | -0.01 | -0.3% | $2.97 | $3.00 | $2.902 | 37,200 | |
| $2.98 | +0.11 | +3.8% | $2.90 | $3.68 | $2.86 | 455,700 | |
| $2.87 | +0.01 | +0.3% | $2.956 | $2.965 | $2.86 | 17,100 | |
| $2.86 | -0.15 | -5.0% | $3.05 | $3.14 | $2.86 | 17,600 | |
| $3.01 | +0.08 | +2.7% | $2.97 | $3.06 | $2.96 | 10,900 | |
| $2.93 | -0.08 | -2.7% | $3.02 | $3.19 | $2.88 | 22,000 | |
| $3.01 | -0.40 | -11.7% | $3.45 | $3.45 | $3.00 | 57,800 | |
| $3.41 | +0.36 | +11.8% | $3.12 | $3.557 | $3.06 | 73,000 | |
| $3.05 | -0.10 | -3.2% | $3.17 | $3.20 | $3.00 | 21,000 | |
| $3.15 | +0.06 | +1.9% | $3.05 | $3.406 | $3.05 | 41,700 | |
| $3.09 | +0.01 | +0.3% | $3.06 | $3.238 | $2.94 | 29,500 | |
| $3.08 | -0.20 | -6.1% | $3.20 | $3.28 | $3.06 | 41,000 | |
| $3.28 | +0.02 | +0.6% | $3.36 | $3.609 | $3.27 | 25,000 | |
| $3.26 | -0.17 | -5.0% | $3.46 | $3.49 | $3.26 | 20,600 | |
| $3.43 | +0.08 | +2.4% | $3.35 | $3.52 | $3.27 | 35,000 | |
| $3.35 | -0.19 | -5.4% | $3.39 | $3.57 | $3.22 | 59,200 | |
| $3.54 | -0.64 | -15.3% | $3.00 | $3.65 | $2.88 | 258,200 | |
| $4.18 | -0.71 | -14.5% | $5.15 | $5.15 | $4.101 | 254,800 | |
| $4.89 | -0.12 | -2.4% | $4.94 | $5.00 | $4.711 | 86,800 | |
| $5.01 | -0.16 | -3.1% | $4.67 | $5.40 | $4.621 | 222,700 | |
| $5.17 | -0.49 | -8.7% | $5.58 | $5.692 | $4.93 | 228,518 | |
| $5.66 | -0.54 | -8.7% | $5.65 | $6.00 | $5.42 | 632,861 | |
| $6.20 | +1.03 | +19.9% | $8.25 | $11.20 | $5.50 | 52,405,500 | |
| $5.17 | +0.37 | +7.7% | $4.80 | $5.23 | $4.80 | 36,000 |
Splits
1 split · NASDAQ:JUNS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-75 | Consolidation |
- Ticker
- NASDAQ:JUNS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 6, 2026
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Latest deck · Apr 2, 2026
Investor Presentation (April 2026)
Investor deck · 14 slides
Latest news
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Oct 6, 2026
Closed $2.86 (+18.2%) on Oct 6, 2026
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Aug 5, 2026
Closed $5.77 (-25.7%) on Aug 5, 2026
Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jul 22, 2026
Closed $13.09 (+2.9%) on Jul 22, 2026
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Jul 7, 2026
Closed $16.19 (-2.4%) on Jul 7, 2026
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
May 27, 2026
Closed $17.99 (+4.3%) on May 27, 2026
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq: JUNS) in Connection with its ~$2 Million Registered Direct Offering
May 26, 2026
Closed $17.25 (-3.3%) on May 26, 2026
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
May 21, 2026
Closed $20.31 (+32.1%) on May 21, 2026
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
May 20, 2026
Closed $15.37 (-35.9%) on May 20, 2026
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
May 20, 2026
Closed $15.37 (-35.9%) on May 20, 2026
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
May 4, 2026
Closed $30.23 (+3.3%) on May 4, 2026
Jupiter Neurosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 42 in all · newest Oct 6, 2026 · oldest 2025
- Decks
- 3 decks · latest Apr 2, 2026
Where Jupiter Neurosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:JUNS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:JUNS | BOATS | United States | USD |
Valuation
EV/sales 16.9× against a median of 5.5×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.33M USD
- P/E
- Loss
- EV/sales
- 16.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.88
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Propanc Biopharma, Inc. · NASDAQ:PPCB | US$1.84M | US$1.62M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.39 |
| Argent Biopharma Ltd · ASX:RGT | US$1.80M | US$8.07M | n/a | 75.4× | n/a | n/a | n/a | n/a | n/a |
| Calidi Biotherapeutics, Inc. · AMEX:CLDI | US$1.76M | −US$2.19M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.86 |
| Kala Bio, Inc. · NASDAQ:KALA | US$1.74M | −US$5.49M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 2.76 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Aptevo Therapeutics Inc. · NASDAQ:APVO | US$1.40M | −US$2.88M | n/a | n/a | n/a | 0.4× | n/a | 1.0× | 0.93 |
| Median of the others | US$1.70M | −US$1.88M | 5.5× | 0.4× | −28.1% | 0.0× | 1.60 |
Forecasts
Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -0.26 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Christer Rosén | Founder, Chairman & CEO |
| Saleem Elmasri | CFO |
| Alison D. Silva | President & CBO |
| Alexander Rosén | Co-Founder, CAO |
| Claes Wahlestedt | Co-Founder, Consulting CMO |
| Marshall Hayward | Co-Founder, CSO |
| Shaun P Brothers | Co-Founder, Consulting Head of Scientific Research |
Board
| Director | Role |
|---|---|
| Christer Rosén | Founder, Chairman & CEO |
| Alison D. Silva | President & CBO |
| Holger Weis | |
| Julie Kampf | |
| Marshall Hayward | Co-Founder, CSO |
| Nicholas Hemmerly |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 | −13.6% |
| Q2 2026 | Aug 14, 2026 | −13.7% |
| Q1 2026 | Jun 3, 2026 | −8.4% |
| Q4 2025 | Feb 25, 2026 | −5.0% |
| Q3 2025 | Nov 14, 2025 · After close | −5.2% |
| Q2 2025 | Aug 18, 2025 | 0.0% |
| Q1 2025 | May 15, 2025 · After close | −3.0% |
| Q4 2024 | Feb 26, 2025 | −2.3% |
| Q3 2024 | Dec 23, 2024 · After close | +3.4% |
| Q4 2021 | Jan 5, 2022 |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2021 | Nov 9, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 14 slides | Apr 2, 2026 |
| Investor Presentation (2025) | Investor deck | 10 slides | Dec 9, 2025 |
| Investor Presentation (February 2025) | Investor deck | 18 slides | February 2025 |
Financings
| Raise | Date |
|---|---|
| Convertible Promissory Notes Terms changed: US$6M Buyers: Yorkville Advisors Global, LP (affiliate) ($6 million pre-paid advance, $4 million funded at signing); YA II PN, Ltd. Use of proceeds: Phase 2 Parkinson's trial of JOTROL, Nugevia direct-to-consumer marketing and sales growth, working capital and general corporate purposes | Feb 23, 2026 |
| Common stock under standby equity purchase agreement Announced: up to US$14M Buyers: Yorkville Advisors Global, LP (affiliate) (up to $14 million of Common Stock over 24 months) Use of proceeds: Phase 2 Parkinson's trial of JOTROL, Nugevia direct-to-consumer marketing and sales growth, working capital and general corporate purposes | Oct 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Dec 2, 2024.
- Price
- US$4.00 a share
- Shares offered
- 2,750,000 shares of common stock
- Offering size
- US$11 million
- Listing
- JUNS on the Nasdaq Capital Market
- Shares delivered
- On or about Dec 4, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Oct 1, 2021 |
| Filed publicly | Oct 12, 2021 |
| Amended 22 times | Newest Oct 18, 2024 |
| Shares registered with an exchange | Feb 4, 2022 |
| Declared effective by the SEC | Nov 8, 2024 |
| Final prospectus, with the price | Dec 2, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B3 · Prospectus | Dec 2, 2024 |
| 424B4 · Prospectus | Dec 2, 2024 |
| CERT · Exchange's certificate of listing | Dec 2, 2024 |
| EFFECT · Notice that a registration is effective | Nov 8, 2024 |
| CORRESP · Letter to the SEC | Nov 7, 2024 |
| CORRESP · Letter to the SEC | Nov 7, 2024 |
| S-1/A · Registration statement, amended | Oct 18, 2024 |
| S-1/A · Registration statement, amended | Sep 13, 2024 |
| CORRESP · Letter to the SEC | Sep 13, 2024 |
| UPLOAD · Letter from the SEC | Sep 12, 2024 |
All 81 filings
Open IPO · From the cover of the final prospectus (424B4) filed Dec 2, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 21.8K | 0 | 0 | 233.3K | 638.0K | 1.13M | |
| Cost of revenue | 4.23K | ||||||
| Gross profit | 17.6K | 233.3K | 638.0K | 1.13M | |||
| Research and development | 2.09M | 492.7K | 954.8K | 942.8K | 1.45M | 1.64M | 685.7K |
| Selling, general and administrative | 6.84M | 2.60M | 2.92M | 2.72M | 3.10M | 1.34M | 1.49M |
| Operating income | -8.91M | -3.09M | -3.87M | -3.43M | -3.91M | -1.85M | -2.18M |
| Depreciation and amortization | 43.3K | 694.2K | 784.3K | 179.2K | 210.4K | 553.0K | |
| EBITDA | -3.05M | -3.18M | -2.65M | -3.73M | -1.64M | -1.62M | |
| Interest expense | 66.0K | 248.4K | 218.7K | 740.9K | 114.0K | 13.5K | 317.1K |
| Income before tax | -8.64M | -2.44M | -4.78M | -4.96M | -4.20M | -1.65M | -3.05M |
| Income tax | 179.2K | ||||||
| Net income | -8.64M | -2.44M | -4.78M | -4.96M | -4.38M | -1.65M | -3.05M |
| Earnings per share, basic | -0.25 | -0.08 | -0.18 | -11.31 | -34.62 | -14.20 | -26.15 |
| Earnings per share, diluted | -0.25 | -0.08 | -0.18 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.79M | 3.77M | 28.5K | 64.4K | 330.6K | 208.0K | 1.28K |
| Receivables | 2.64K | 0 | 126.2K | ||||
| Inventory | 159.8K | 0 | |||||
| Current assets | 4.82M | 4.65M | 28.7K | 69.7K | 454.7K | 550.0K | 4.97K |
| Total assets | 5.56M | 6.20M | 148.6K | 235.9K | 667.4K | 550.0K | 6.18K |
| Accounts payable | 131.1K | 278.7K | 189.5K | 187.0K | 256.9K | 252.2K | 131.1K |
| Current liabilities | 7.40M | 2.01M | 5.77M | 7.26M | 5.68M | 4.26M | 5.02M |
| Long-term debt | 106.7K | ||||||
| Total debt | 5.32M | 217.8K | 2.25M | 1.90M | 651.2K | 108.5K | 1.21M |
| Total liabilities | 7.40M | 2.03M | 5.95M | 7.38M | 5.85M | 4.26M | 5.02M |
| Shareholders' equity | -1.83M | 4.17M | -5.80M | -7.14M | -5.18M | -3.71M | -5.02M |
| Shares outstanding | 459.3K | 33.1M | 26.5M | 438.4K | 126.5K | 116.5K | 116.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -5.41M | -3.91M | -481.0K | -1.25M | -1.74M | -254.8K | -143.0K |
| Capital spending | -4 | -4 | -3 | -4 | -4 | 0 | 0 |
| Free cash flow | -5.41M | -3.91M | -481.0K | -1.25M | -1.74M | -254.8K | -143.0K |
| Cash from financing | 5.43M | 7.65M | 445.0K | 982.3K | 1.86M | 461.5K | 107.8K |
| Change in cash | 19.8K | 3.74M | -36.0K | -266.2K | 122.6K | 206.7K | -35.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 26, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Oct 9, 2026 | Offer document | SEC |
| S-3 · Registration statement | Sep 24, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 22, 2026 | Big-stake notice | SEC |
| D | Sep 4, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 27, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
| 8-K · Current report | Aug 24, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 24, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jul 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 28, 2026 | Financing | SEC |
| 424B3 · Prospectus | Jul 27, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 27, 2026 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Jul 22, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jul 21, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 21, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2026 | Management or board change | SEC |
| S-1 · Registration statement | Jun 26, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Jun 22, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 22, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 22, 2026 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Jun 9, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Jun 5, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 21, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 21, 2026 | Offer document | SEC |
| 8-K · Current report | May 21, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 21, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 20, 2026 | Offer document | SEC |
| 8-K · Current report | May 20, 2026 | Current report | SEC |
| 424B3 · Prospectus | May 14, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | May 8, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 15, 2026 | Offer document | SEC |
| 10-K · Annual report | Apr 1, 2026 | Annual report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2026 | Explanation request | SEC |
| 8-K · Current report | Feb 27, 2026 | Current report | SEC |
| 8-K · Current report | Feb 20, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Feb 13, 2026 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-1 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Nov 20, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 7, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 6, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 6, 2025 | Meeting notice | SEC |
| PRER14A | Oct 27, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 27, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Oct 17, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 18, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 8-K · Current report | Jul 9, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 21, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 23, 2024 | Quarterly report | SEC |
| 8-K · Current report | Dec 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 19, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 4, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Dec 2, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 19, 2024 | Material contract | SEC |
| SC 13D · Big-stake notice | Nov 15, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 15, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 15, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 15, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Nov 15, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 13, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Nov 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 7, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Oct 18, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Sep 13, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 12, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 4, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 3, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 7, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 12, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 15, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 15, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 17, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 13, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 6, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 7, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 7, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 6, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 2, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 20, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 20, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 12, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 12, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 26, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 26, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 25, 2022 | Other filings | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 24, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 16, 2022 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 18, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 5, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 5, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 4, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 4, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 4, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 3, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 25, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 14, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 10, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2022 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Feb 4, 2022 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 4, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 3, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 2, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 2, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 31, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 26, 2022 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 5, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 23, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 23, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 22, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 17, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 17, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 19, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 9, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 9, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 28, 2021 | Other filings | SEC |
| S-1 · Registration statement | Oct 12, 2021 | Offer document | SEC |
This page holds 200 of 204 filings. Open Filings
Cap table
Built by 6ix from Jupiter Neurosciences, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 1,318,521
- Fully diluted
- 1,318,521
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,318,521 | Nov 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 1,318,521 |
| Aug 5, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Holger Weis Other companies: Alaunos Therapeutics, Inc. (Chairman and Chief Executive Officer · Since at least Dec 15, 2020) | Director · Since at least Nov 8, 2024 |
| Julie Kampf Other companies: Marizyme, Inc. (Director · Mar 5, 2021 – Jun 7, 2022 · Past) | Director · Since at least Nov 8, 2024 |
| Nicholas Hemmerly Other companies: Liberty Star Uranium & Metals Corp. (Director · Since at least Sep 26, 2022) | Director · Since at least Nov 8, 2024 |
| Saleem Elmasri Other companies: Liberty Star Uranium & Metals Corp. (Director · Since at least Aug 14, 2023) | CFO · Since at least Nov 8, 2024 |
| Alexander Rosén | Co-Founder, CAO · Since at least Nov 8, 2024 |
| Alison D. Silva | President & CBO · Since at least Nov 8, 2024 |
| Allison W Brady | Director · Since at least Nov 8, 2024 |
| Andrew Jon Cutler | Director · Since at least Jul 22, 2026 |
| Christer Rosén | Founder, Chairman & CEO · Since at least Nov 8, 2024 |
| Claes Wahlestedt | Co-Founder, Consulting CMO · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Marshall Hayward | Co-Founder, CSO · Since at least Nov 8, 2024 |
| Shaun P Brothers | Co-Founder, Consulting Head of Scientific Research · Since at least Nov 5, 2026 |
| Tomas Jan Philipson | Director · Since at least Jun 26, 2026 |
Log in to ask 6ix AI your own questions about Jupiter Neurosciences, Inc.